Meta Pixel

News and Announcements

Knowing The Sentiment And Strategy Of Investors

  • Published December 12, 2022 7:29AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

These questions help you learn more about the sentiment and strategy of investors so that you can create your own vetted list of potential candidates 👇

đź“‹ What kinds of investments do they prefer?

🏪 Which markets or industries are they interested and experienced in?

📊 Typically, what stage of business do they consider?

âś… Are they able to add any substantive value to the management team, and do they remain poised under pressure?

🤝 Do they have a reputation for following through on promises and closing on their term sheets?

đź’Ş Whom do they syndicate with?

đź’° Who will be the lead partner and how do they fit with your venture?

🤔 Where is the lead investor in the life of their fund?

đź’¸. Is there follow-on money reserved, or are they near the end of the fund and ready for another raise from their limited partners?

🤠 Are the investors bullish, coming off a successful fund, or anxious, coming off a failing one?

The time is always right for raising money on good terms from the best investors 👍

If you put in the effort, when the conditions dictate, you will know whom to talk to 🙌

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now